IGF-DES
Low EvidenceA truncated form of IGF-1 with high potency and rapid local activity at the site of administration.
What It Is
IGF-DES (Des(1-3) IGF-1) is a truncated variant of insulin-like growth factor-1 missing the first three N-terminal amino acids (Gly-Pro-Glu). This truncation virtually eliminates binding to IGF-binding proteins (IGFBPs), making IGF-DES the most potent form of IGF-1 available in terms of free bioactivity. Without IGFBP regulation, IGF-DES exhibits approximately 10× greater potency than native IGF-1 in cell proliferation assays and has a very short half-life (approximately 20–30 minutes), producing rapid but transient IGF-1R activation. IGF-DES was originally identified as a naturally occurring variant in human brain tissue, where it is thought to act in an autocrine/paracrine fashion. Its extreme potency and lack of IGFBP buffering make it particularly high-risk from a safety perspective — unregulated IGF-1R signaling promotes cell proliferation pathways implicated in tumor growth and progression. Research applications are primarily limited to in vitro cell biology and tissue engineering where precise, short-duration IGF-1R stimulation is needed. IGF-DES has no clinical trial history, is classified as prohibited by WADA, and is not FDA-approved for any indication.
Why Researchers Study It
Des(1-3) IGF-1 lacks the first three amino acids of native IGF-1, which eliminates binding to IGF-binding proteins entirely. This results in dramatically increased bioactivity at the IGF-1 receptor, making it a potent research tool for studying maximal IGF-1 receptor activation and its downstream effects on cell proliferation.
Proposed Mechanisms
- Binds IGF-1 receptor with full affinity but cannot be sequestered by IGF-binding proteins
- Approximately 10x more potent than native IGF-1 at receptor activation
- Stimulates rapid cell proliferation and protein synthesis
- Very short half-life concentrates activity at local injection site
Evidence Snapshot
Commonly Discussed Benefits
Safety & Cautions
- Extremely potent growth factor
- Theoretical concerns about uncontrolled cell proliferation
- Very short half-life requires precise administration
- Not FDA-approved; limited human safety data
Comparisons
See how IGF-DES compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Ballard FJ. et al. — Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
CJC-1295
Medium EvidenceA growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
Ipamorelin
Medium EvidenceA selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
IGF-1 LR3
Medium EvidenceA modified form of IGF-1 with extended half-life, studied for muscle growth and tissue development.
PEG-MGF
Low EvidenceA PEGylated splice variant of IGF-1 studied for muscle repair and satellite cell activation, with an extended half-life compared to native MGF.